Acute Porphyria Drug Database

C09CA06 - Candesartan
Not porphyrinogenic
NP

Rationale
Mainly eliminated in unchanged form, in minor parts metabolised by CYP 2C9. One reference and clinical observations point to non- porphyrinogenicity.
Chemical description
Angiotensin II receptor antagonist. Mainly eliminated in unchanged form, to a lesser extent metabolized in the liver by 2C9. Less potent inhibitor of CYP 2C9. Thunell, patient reports (n=5): tolerated. Andersson, patient report (n=1): tolerated. French list: authorized
IPNet drug reports
Uneventful use reported in 44 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes C09C / C09CA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙